Research · 4 min read
What the MASH Indication Added to a GLP-1 Label
A GLP-1 label now carries a liver-disease indication with a fibrosis stage written into it. The wording is narrow, it excludes cirrhosis, and it is not what a weight-loss page is selling.
Key takeaways
- The indication is narrow on its face: noncirrhotic MASH, with fibrosis the label describes as consistent with stages F2 to F3, in adults.
- It is one of several separate indications on the same label, each reached by its own evidence — an approved use is a specific claim about a specific population, not a general endorsement of the molecule.
- The label states a maintenance dosage for this use, which is a prescriber's decision and depends on a diagnosis and a stage that require testing.
- The supporting trial the label describes enrolled 1,195 adults and treated 800 of them for a median of 95.3 weeks against placebo.
- The label carries a limitation of use against combining it with other semaglutide-containing products or any other GLP-1 receptor agonist.
- No compounded product carries this or any other FDA-approved indication, so a liver claim attached to a compounded semaglutide offer has gone past its evidence.
Answer first: the indication names a disease, a stage, and an age
The current prescribing information for Wegovy lists, among its indications, use "for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults."
Every clause in that sentence is doing work. "Noncirrhotic" excludes people whose liver disease has progressed to cirrhosis. "Moderate to advanced liver fibrosis" is narrowed further by the parenthesis to stages F2 to F3, which is a staging scale a pathologist or an imaging test produces, not something a person knows about themselves from a symptom. "In adults" excludes the adolescent population that appears elsewhere in the same indications section for a different use.
So the indication is not "for fatty liver." It is for one named condition, at two named stages, in adults, and only where cirrhosis has not developed. A page that shortens it to anything broader has widened a claim the label did not make.
The same molecule, a different question
The indications section of this label carries several distinct uses. Alongside the MASH indication it lists reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and reducing excess body weight and maintaining weight reduction long term in stated populations.
These are separate indications reached by separate evidence, and the label states them separately. That matters for a reader comparing sellers, because an approved use is granted for a specific claim on a specific population — it is not a general endorsement of the molecule. A company that sells a compounded semaglutide product for weight is not selling a MASH treatment, and nothing about this indication reaches that product.
The label also carries a limitation of use that constrains how the drug may be combined: "Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended." A reader holding two subscriptions from two sellers is the person that sentence is about.
The label sets a strength for this use, and it is a prescriber's decision
The label states: "The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly."
That sentence is quoted here for one reason: it shows that the approved use comes with a specified maintenance strength rather than being open-ended. It is not an instruction to anyone. Whether any drug is appropriate for a person, at what strength, and for how long, is a decision for a prescriber who can see that person's records — and in this case one who can see a fibrosis stage, which requires testing.
It is also the clearest reason a MASH indication cannot be inferred from a weight-loss offer. The route into this use runs through a diagnosis and a stage, not through an online intake form that asks for a height and a weight.
What the trial behind it enrolled
The label describes the supporting study as "a randomized, double-blind, placebo-controlled trial (Study 11) that included 1,195 adult patients with MASH, including 800 patients who were exposed to WEGOVY for a median of 95.3 weeks and 395 patients who were exposed to placebo for a median of 83.1 weeks."
Two things in that sentence are worth a reader's attention. The first is the exposure duration: a median of roughly 95 weeks in the treated group is close to two years, which is a different order of commitment from the twelve-week framing common on marketing pages. The second is that it was placebo-controlled, which means the comparison was against placebo — not against another GLP-1, and not against a compounded product.
This site does not restate trial results beyond what a label prints, and it does not tell anyone what a result means for them. What the enrollment figures establish here is narrower and still useful: the population studied was adults with MASH, and the study ran long.
Why this matters when you are comparing sellers
An approved indication belongs to an approved product. It does not travel to a compounded version of the same active ingredient, because a compounded preparation is not an FDA-approved drug and carries no FDA-approved indication at all. A seller that lists semaglutide and mentions liver benefits is not offering something the label reaches.
The narrowness also explains a mismatch a reader may notice between a label and an advertisement. Marketing tends to describe a molecule; a label describes permitted claims about a population. When the two disagree, the label is the document with an agency judgment behind it.
The practical test is the one this site applies everywhere: read what the seller actually publishes, and check whether the claim on the page is a claim the label makes. If a page implies a liver indication for a product that is not the approved product, the page has gone past its evidence.
Sources
- WEGOVY (semaglutide) injection — Highlights of Prescribing Information and full prescribing informationThe MASH indication wording quoted in full, including the terms noncirrhotic, the former name NASH, the fibrosis description consistent with stages F2 to F3, and the restriction to adults; the presence of separate cardiovascular-risk and weight-reduction indications on the same label; the limitation of use against concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist; the sentence naming the recommended maintenance dosage for the MASH use; and the description of Study 11 as a randomized, double-blind, placebo-controlled trial of 1,195 adult patients with MASH, with 800 exposed to the drug for a median of 95.3 weeks and 395 to placebo for a median of 83.1 weeks.
Frequently asked questions
What does the MASH indication on this label actually say?
It covers treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, described on the label as consistent with stages F2 to F3, in adults. Each clause narrows it: cirrhosis is excluded, the fibrosis stage is specified, and the population is adults.
Is MASH the same thing as NASH?
The label treats the newer name as replacing the older one. Its indication wording says metabolic dysfunction-associated steatohepatitis, "formerly known as nonalcoholic steatohepatitis (NASH)." A document using either name may be describing the same condition.
Does a compounded semaglutide product carry this indication?
No. A compounded preparation is not an FDA-approved drug and carries no FDA-approved indication. An indication is granted to a specific approved product on specific evidence, and it does not transfer to a different preparation because the active ingredient shares a name.
Does the label say anything about combining this with another GLP-1?
Yes. It states that concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. That is a limitation printed on the label itself.
How long were people in the supporting trial treated?
The label reports that of 1,195 adults with MASH in the trial it calls Study 11, 800 were exposed to the drug for a median of 95.3 weeks and 395 received placebo for a median of 83.1 weeks.
Can a telehealth intake tell whether someone has F2 to F3 fibrosis?
A fibrosis stage comes from testing, not from the height, weight and history questions an online intake asks. Nothing on this site can tell a reader their stage, and a form that does not test cannot establish the criterion the indication names.